In the past, differential profiling and functional studies have been performed mainly using tissues samples collected by invasive methods. However, in a clinical setting, more convenient and non-invasive methods are required, such as collection of peripheral blood or other bodily fluids:

  • Circulating Blood Plasma,
    • both Free Circulating[1]
    • and within Exosomes[2]
  • Cerebral Spinal Fluid[3],
  • Urine[4,5]
  • Breast Milk[6]
  • Saliva

  1. Liquid biopsies remove the need for invasive, often painful surgeries and procedures for which there is risk of infection or other complications for the patient.
  2. The convenience of liquid biopsies means samples can be taken repeatedly over the course of a patient’s treatment and changes can indicate how effective or ineffective a particular therapy is.
  3. Liquid biopsies can detect disease progression or treatment resistance long before it would trigger clinical symptoms.
  4. Limitation of adequate amounts of patient specimens is generally not a problem.

Exosomes

Exosomes are small membrane vesicles secreted by most cell types that play important roles in cell-to-cell communication. There is a rapidly growing interest in utilizing exosomes present in patient biofluids for molecular diagnostics in the clinic.

Recent studies suggest that exosomes secreted by tumor cells contain tumor specific proteins and miRNAs and therefore exosomes may contribute to intercellular communication within the tumor niche. In fact, in vitro delivery of exosomes purified from high grade cancer was found to significantly increase cell proliferation and promote cancer progression.

Additionally, exosomes are attractive as potential therapeutic delivery vehicles as they are natural shuttles of RNA and protein cargo.

Plasma Sample

It has been demonstrated that microRNAs are present in circulating blood plasma, protected from degradation by inclusion in lipid or lipoprotein complexes. Circulating microRNAs in plasma/serum represent a potential new approach for diagnostic screening. Indeed, characteristic changes in the serum or plasma miRNA profiles of several cancers or other conditions have identified unique signatures that could be exploited as novel biomarkers in the clinic.

Additionally, plasma/serum microRNA panels developed through extensive case-control genome-wide expression have considerable clinical value in determining patient prognosis. Expression levels of particular microRNAs could serve as a biomarker for worse survival of patients, and thus could serves as an important prognostic marker. Studies suggest that identifying and validating the expression of miRNAs in newly diagnosed patients could serve as potential biomarker for tumor aggressiveness, and such miRNAs could be useful for the screening of high-risk patients.

urine sample

Investigating cellular pathophysiology through the study of intracellular biomarkers in various biofluids such as urine, breast milk and even cerebral spinal fluid has the potential of providing a deeper understanding of how individuals express unique patterns of various pathologies.

Ultimately, personalized therapeutic approaches to controlling these illnesses will result from these new diagnostic techniques. Recently this was demonstrated by a study highlighting a common clinical scenario. Multiple tissue biopsies were completed and failed to obtain critical clinical information, and finally a urine based liquid biopsies test confirmed the presence of a resistance mutation in non-small cell lung cancer[7].


Presented by – Dr. Moemen Abdalla, Norgen Biotek and Dr. Christoph Eicken , LC Sciences

Webinar Outline

  • Brief review of microRNA basics: history, biogenesis, function
  • Recent developments of microRNA research in extracellular fluids and exosomes
  • Current methods for sample preservation and extraction of various complex extracellular sample types including exosomes
  • Current methods for microRNA discovery and profiling from extracellular sample types
  • Case studies and application examples



LC Sciences offers a range of services applicable to clinical cancer research . Contact us to find out more.


VariantPro™ Targeted Sequencing

The VariantPro system is an innovative multiplex PCR based targeted sequencing method that accomplishes target selection, library preparation and molecular tagging in a simple one-step workflow. [learn more…]

Exome Sequencing

Exome sequencing is an efficient strategy to selectively sequence the coding regions of the genome as a less expensive but still effective alternative to whole genome sequencing. [learn more…]


Cancer Antigen Arrays

The additional knowledge gained by studying the response to antigens at the epitope level will help us further understand anti-tumor immunity and may also help us to monitor cancer progress and cancer vaccine efficacy in the future. [learn more…]

Protein Profiling Arrays

Systems Biology has emerged as an effective approach to studying complex interactions within biological systems. By studying entire networks or pathways, we can better understand the underlying structure of cell signaling networks. [learn more…]


microRNA Profiling

microRNAs are small noncoding RNA molecules that function broadly as negative regulators of gene expression to control a wide range of cellular processes. [learn more…]

RNA Sequencing

Our comprehensive sequencing services make use of the latest in next-gen sequencing technologies. Illumina’s industry-leading RNA sequencing methods enable discovery [learn more…]